NCT00418704

Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)

A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Groupe Francais De Pneumo-Cancerologie · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.

Detailed description

A multicenter phase II trial , prospective, randomized, open, non comparative

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Erlotinib	Tarceva (150 mg) is a pill you take once a day -- every day
DRUG	taxotere	Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.

Timeline

• Start date: 2006-05-01
• Primary completion: 2006-06-01
• Completion: 2009-06-01
• First posted: 2007-01-05
• Last updated: 2013-10-01

Locations

22 sites across 1 country: France